Fusion Antibodies (FAB) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Jul 2020 02:12 PM
RNS
Exercise of Options
06 Jul 2020 04:41 PM
RNS
Second Price Monitoring Extn
06 Jul 2020 04:36 PM
RNS
Price Monitoring Extension
06 Jul 2020 07:00 AM
RNS
Trading update
04 Jun 2020 12:57 PM
RNS
Holding(s) in Company
29 May 2020 05:00 PM
RNS
Total Voting Rights
21 May 2020 06:24 PM
RNS
Holding(s) in Company
21 May 2020 02:52 PM
RNS
Holding(s) in Company
15 May 2020 04:49 PM
RNS
Holding(s) in Company
15 May 2020 10:47 AM
RNS
Result of General Meeting & Total Voting Rights
15 May 2020 08:30 AM
RNS
Holding(s) in Company
28 Apr 2020 07:00 AM
RNS
Placing to raise £3m, trading update, notice of GM
17 Apr 2020 04:41 PM
RNS
Second Price Monitoring Extn
17 Apr 2020 04:35 PM
RNS
Price Monitoring Extension
16 Apr 2020 04:41 PM
RNS
Second Price Monitoring Extn
16 Apr 2020 04:36 PM
RNS
Price Monitoring Extension
16 Apr 2020 03:51 PM
RNS
Research Alliance with Queen's University Belfast
16 Apr 2020 02:06 PM
RNS
Second Price Monitoring Extn
16 Apr 2020 02:01 PM
RNS
Price Monitoring Extension
30 Mar 2020 07:00 AM
RNS
Trading update
19 Mar 2020 07:00 AM
RNS
Belfast investor presentation
17 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
17 Feb 2020 07:00 AM
RNS
Belfast investor presentation
03 Feb 2020 12:01 PM
RNS
Director/PDMR Shareholding
30 Jan 2020 04:40 PM
RNS
Second Price Monitoring Extn
30 Jan 2020 04:35 PM
RNS
Price Monitoring Extension
29 Jan 2020 07:00 AM
RNS
Trading update
10 Jan 2020 11:47 AM
RNS
Director/PDMR Shareholding
03 Dec 2019 09:26 AM
RNS
Director/PDMR Shareholding
02 Dec 2019 07:00 AM
RNS
Half-year Report
26 Nov 2019 11:13 AM
RNS
Notice of Results
22 Oct 2019 07:00 AM
RNS
Half year trading update
26 Sep 2019 09:54 AM
RNS
Director/PDMR Shareholding
20 Sep 2019 02:14 PM
RNS
Result of AGM
21 Aug 2019 07:00 AM
RNS
Posting of Annual Report & Notice of AGM
03 Jul 2019 04:09 PM
RNS
Director/PDMR Shareholding
02 Jul 2019 07:00 AM
RNS
Final Results
29 Apr 2019 02:46 PM
RNS
Director/PDMR Shareholding
25 Apr 2019 04:40 PM
RNS
Second Price Monitoring Extn
25 Apr 2019 04:35 PM
RNS
Price Monitoring Extension
18 Apr 2019 07:00 AM
RNS
Investor presentation
17 Apr 2019 07:00 AM
RNS
Trading Update
25 Feb 2019 07:00 AM
RNS
Trading Statement
21 Dec 2018 07:00 AM
RNS
Grant of Options
17 Dec 2018 07:00 AM
RNS
Launch of Rational Affinity Maturation Platform
03 Dec 2018 01:39 PM
RNS
Director/PDMR Shareholding
26 Nov 2018 07:00 AM
RNS
Half-year Report
19 Nov 2018 07:00 AM
RNS
Notice of Results
25 Sep 2018 02:23 PM
RNS
Director/PDMR Shareholding
24 Sep 2018 04:13 PM
RNS
Director/PDMR Shareholding

Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.

FAB share price launched at 165p in 2017.

UK 100

Latest directors dealings